Mephentermine and phentermine, substances prohibited in sports by the World Anti-Doping Agency, were found for the first time in urine specimens following the administration of a therapeutic medication, oxethazaine. In a recent sporting event, a urine specimen donor who tested positive for mephentermine and phentermine claimed consumption of Mucaine ® for treating stomach pain was the reason for testing positive. Five volunteers were administrated oxethazaine (a topical anesthetic found in the multi-ingredient medication Mucaine and its generic equivalent, Stoin, both of which are available in Taiwan), mephentermine, and phentermine. Excretion profiles of mephentermine and phentermine following the administration of these drugs were found to be similar. However, the mephentermine/phentermine ratios found in urine specimens collected at different time points following the administration of oxethazine and mephentermine were found to be characteristically different.
Introduction
It is now well-known that administration of certain therapeutic drugs, such as selegiline, famprofazone, fencamine, furfenorex, and dimethylamphetamine, can result in the detection of commonly abused amphetamine and methamphetamine (1) (2) (3) . An in-competition urine sample donor at a recent sporting event in Taiwan tested positive for mephentermine (MPT) and phentermine (PT) and claimed taking Mucaine for treating stomach pain. Because information provided by this drug's manufacturer indicated the presence of oxethazaine (N,N-bis-N-methyl-N-phenyl-t-butylacetamido)-β-hydroxyethylamine or OXZ) (Figure 1 ) as the main component (4), we have conducted a limited metabolic study of OXZ (5) to ascertain whether oral administration of OXZ can indeed result in the detection of MPT and PT in urine and, if so, whether the excretion profiles of these compounds can be used to differentiate whether their occurrence comes from the administration of OXZ, MPT, or PT. methanol as stock solutions. Prior to the study, three healthy male and two female volunteers (age range 25-37 years, body weight range 50-85 kg) signed informed consents approved by the Human Subject Research Review Committee (Tzu Chi General Hospital, Taipei, Taiwan). A single Stoin tablet (containing 5 mg OXZ) was administered orally to each human subject in the morning. Food and water were available ad libitum throughout the course of the study.
To understand whether the excretion profile resulting from the administration of OXZ is different from the administration of MPT or PT, two separate excretion studies using 10-mg dose of MPT and PT were also performed. To avoid potential interference of residual metabolites, a twoweek administration interval was followed for these excretion studies.
Urine specimens were collected from the subjects according to the following schedule after drug administration: 0 (pre-administration of drug), 2, 4, 6, 8, 12, 24, 48, and 72 h. Urine specimen collected at each time point was stored at -20°C. If one or more void was collected before the next collection time point, the collection(s) would be combined with that collected at the later time point. Specific gravity and pH of each urine specimen were measured using a refractometer (Atago, Tokyo, Japan) and a pH meter (Mettler-Toledo Pac Rim AG, Taipei, Taiwan) before the sample preparations step. These were found to be normal, as further described in the Results and Discussion section.
Extraction and derivatization
Urine specimens from the three excretion studies were analyzed according to the standard analytical procedures of the Tzu Chi University Doping Control Laboratory for non-conjugated volatile stimulants and narcotics. Specifically, 50 µL phenoxazine (20 µg/mL), serving as the IS, was spiked into each 4-mL urine sample contained in a 20-mL glass tube. The pH of the sample was adjusted to pH 9-9.5 using 2 g NaHCO 3 /K 2 CO 3 (3:2, w/w), then extracted by 3 mL t-butylmethylether with agitation and centrifugation at 2000 rpm for 10 min. The organic phase was evaporated to dryness under a stream of nitrogen at 40°C. Each sample residue was reconstituted with 100 µL ethyl acetate and derivatized by adding 100 µL of TFAA, heating at 70°C for 20 min, and then evaporating to dryness. Not knowing its stability, the resulting product was immediately reconstituted with ethyl acetate (typically 500 µL) and analyzed by GC-MS (7).
Instrumentation and operational parameters
A Hewlett-Packard (HP, Palo Alto, CA) model 6890 GC equipped with a G1512A autosampler interfaced to a 5973 mass selective detector (MSD) was used for sample analysis. The GC was equipped with a BPX-5 fused-silica capillary column (25 m × 0.22-mm i.d., 0.25-µm film thickness) from SGE International (Ringwood, Victoria, Australia). The carrier gas was helium at a flow rate of 1.0 mL/min. Temperatures for the GC injection port, interface, ion source, and quadruple were maintained at 250, 300, 230, and 150°C, respectively. The GC oven conditions were operated as follows: the initial temperature was 90°C, followed by increasing 15°C/min to 240°C, and 10°C/min to 300°C (holding time 15 min). Solvent blanks were injected between samples to avoid the potential carryover problem. The mass spectrum was obtained by scanning from m/z 50 to 550. The MS was operated in electron impact mode at an electron ionization energy of 70 eV. Splitless injection mode was used, and the injection volume was 1 µL.
Data acquisition and analysis were executed with HP G1701AA version 0.300 Chemstation Software in the drug analysis mode. Full-scan mass spectrometric data were stored as digital files that were then converted into mass spectra of a more desirable format for presentation. This conversion was carried out using the DeltaGraph software (DeltaPoint, Seattle, WA) followed by the compilation of the resulting mass spectra using the Adobe ® PageMaker software (Adobe Systems, San Jose, CA). Both software systems were run on an Apple iMac G5 computer (Cupertino, CA).
Results and Discussion
Mass spectra of TFA-derivatized MPT, PT, and the IS shown in Figure 2A -2C were obtained from standard solutions containing these compounds. Retention time and mass spectrum information were then used for qualitative and quantative determinations of these compounds for the evaluation of various analytical parameters and the determination of the excretion profiles following the administration of OXZ, MPT, and PT. Determination of OXZ was not attempted.
Evaluation of analytical parameters
Recovery. To determine the recovery (or extraction efficiency) of the sample preparation procedure, three target concentrations (7.5, 35, and 75 ng/mL), each with six replicates, of MPT and PT were analyzed. Two sets (A and B) of these standards were prepared with the IS added before and after the extraction step. Recoveries were calculated by dividing the mean peak-area ratio of set A by the corresponding peak-area ratio of set B and then multiplying by 100%. The mean recoveries thus calculated for the standards at 7.5, 35, and 75 ng/mL were 82%, 115%, and 97%, respectively, for MPT and 83%, 88%, and 90%, respectively, for PT. Another set of recovery studies was conducted using standards at higher concentrations (0.25, 7.5, and 45 µg/mL); the recoveries of MPT and PT for these standards were 112%, 93%, and 86% and 106%, 91%, and 94%, respectively. These two sets of recovery data derived from the lower and higher concentration ends are all well within ± 20% of the targeted value (100%).
Calibration and limits of detection (LOD) and quantification (LOQ).
Detector response linearity was evaluated by preparing calibration curves using two sets of MPT-and PT-fortified urines at the higher (0.10, 0.50, 1.0, 5.0, 10, 20, 30, 40, and 50 µg/mL) and lower (5.0, 10, 25, 50, and 100 ng/mL) concentrations. Regression curves were obtained by plotting peak-area ratios (analyte/IS peak area) versus concentration using the least-squares method. In all cases, the correlation coefficient (R 2 ) and percent coefficient of variance (%CV) were > 0.995 and < 10%, respectively.
The LOD of the assay was determined mathematically and defined as the concentration of the analyte that produces a signal-to-noise (S/N) ratio ≥ 3 using single diagnostic ions m/z 168 and 154 for MPT and PT, respectively. The LOQ of the assay was also determined mathematically and defined as the concentration of the analyte that produces a S/N ratio ≥ 10, again using the same diagnostic ions (8, 9) . The LOQs for the analysis of MPT and PT using the protocol described earlier were determined (n = 7) to be 5.0 and 8.3 ng/mL, respectively.
Accuracy and precision. Intra-and interassay accuracy and precision were determined using five replicates at two (low and high) concentration levels. At the low concentration end, three sets of standards (each with five replicates) were prepared at 7.5, 35, and 75 ng/mL, and at the higher concentration end, the standard concentrations were 7.5, 15, and 45 µg/mL. The resulting accuracy and % CV for the analytes at the lower and higher concentration ends are shown in Table I . With this information, we have concluded the analytical data are reproducible. "Accuracy" is defined here as the closeness of the analytical findings to the concentrations of the analytes as prepared for the standard solutions. Because no primary standard is available, we could not assess the accuracy of the concentrations of the standard solution prepared in house.
Excretion profiles following the administration of OXZ, MPT, and PT
With the two specific objectives in mind (determining whether oral administration of OXZ can indeed result in the detection of MPT and PT in urine; and if so, whether the excretion profiles of these compounds can be used to differentiate whether their occurrence comes from the administration of OXZ, MPT, or PT), we are particularly interested in the analytes' concentrations and the analytes' concentration ratios at spe- 
Detection of MPT and PT following the ingestion of OXZ
The excretion profiles of MPT and PT exhibited by the five subjects (A, B, C, D, and E), following the administration of OXZ, MPT and PT, are presented in Figure 3 in the first, second, and third column, respectively. Because no analyte was detected at time 0, the two-week interval between drug administrations was long enough for complete clearance of the drug previously administrated. Information shown in Figure 3 clearly confirms the detection of MPT and PT following the ingestion of OXZ, which is the primary objective of this study.
As stated earlier, with various limitations (e.g., limited number of subjects, no data on fluid intake and blood sample, and the pooling of samples collected between the preset time intervals), data presented in Figure 3 cannot be used to derive exact pharmacokinetic parameters. However, these profiles point to near-complete excretion of these drugs in 72 h.
Differentiating the ingestion of OXZ, MPT, and PT
As shown in Figure 3 , the ingestion of PT is characterized by the absence of MPT. On the other hand, it is not as obvious whether OXZ or MPT is ingested. Shown in Table II are the MPT/PT concentration ratio information for the data shown in Figure 3 and the MPT/PT ratio of their amounts accumulated at each time point. Data shown in this table indicate when significant amounts of MPT and PT are present. The MPT/PT ratios found in urine collected following the administration of OXZ are typically lower than 1, and significantly higher MPT/PT ratios are observed when MPT was administrated. This ratio parameter can be very useful to differentiate whether OXZ or MPT is ingested.
Conclusions
With a limited excretion study, we have confirmed that ingestion of OXZ, an ingredient found in several over-the-counter medicines, can result in the detection of MPT and PT. Furthermore, when significant amounts of these compounds remain in urine, it is possible to use the MPT/PT concentration ratio to determine whether the MPT and PT detected is a result of OXZ or MPT ingestion.
